АТОРВАСТАТИН В ЛЕЧЕНИИ ГИПЕРХОЛЕСТЕРИНЕМИИ И АТЕРОСКЛЕРОЗА: КРИТЕРИИ ВЫБОРА ДОЗЫ В РАЗЛИЧНЫХ ПОПУЛЯЦИЯХ ПАЦИЕНТОВ

1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001, 285 (19): 2486-2497.

2. Jones P, Kafonek S., Laurora I., Hunninghake D., for the CURVES Investigators. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin and fluvastatin in patients with hypercholesterolemia (the CURVES Study). Am J Cardiology 1998: 81 (5): 582-587.

3. Pitt B, Waters D, Brown WV et al. Aggressive lipidlowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators. N Engl J Med 1999; 341: 70-76.

4. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383–9

5. Athyros VG, Mikhailidis DP, Papageorgiou AA et al. Effect of atorvastatin on high density lipoprotein cholesterol and its relationship with coronary events: a subgroup analysis of the GREek Atorvastatin and Coronary heart- disease Evaluation (GREACE) Study. Curr Med Res Opin 2004, 20 (5): 627-637.

6. Pedersen TR, Faergeman O, Kastelein JJ et al. High- Dose Atorvastatin vs Usual-Dose Simvastatin for Secondary Prevention After Myocardial Infarction. The IDEAL Study: A Randomized Controlled Trial. JAMA 2005,294: 2437-2445.

7. Amarenco P, Bogousslavsky J, Callahan A. 3rd et al. High-Dose Atorvastatin after Stroke or Transient Ischemic Attack. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL). N Engl J Med 2006, 355: 549-59.

8. Cannon CP, Braunwald E, McCabe CH et al. Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes. Pravastatin or Atorvastatin Evaluation and Infection Therapy– Thrombolysis in Myocardial Infarction 22. N Engl J Med 2004, 350:1495-504.

9. LaRosa JC, Grundy SM, Waters DD et al; Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005, 352 (14):1425-35.

10. Nawrocki JW, Weiss SR, Davidson MH et al. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesteroleamia by atorvastatin, a new HMG-Ko-A reductase inhibitor. Arteriosclerosis Thromb Vascular Biology 1995, 15: 678-682.

11. Jones PH, Davidson MH, Stein EA. et al. STELLAR Study Group. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol 2003;92 (2):152-60.

12. Andrews T. C., Ballantyne C. V., Hsia J. A. et al. Achieving and maintaining National Cholesterol Education Program low–density lipoprotein cholesterol goals with five statins. Am J Med., 111 (3), 185-91.

13. Karalis D. G., Ross A. M., Vacari R. M. Comparison of efficacy and safety of atorvastatin and simvastatin in patients with dyslipidemia with and without coronary heart disease. Am J Cardiol 2002, 89 (6): 667-71.

14. Jones P. H., McKenney J.M., Karalis D. G. Comparison of the efficacy and safety of atorvastatin initiated at different starting doses in patients with dyslipidemia. Evide Based Cardiovasc Med 2005, 9 (2):98-101.

15. Schrott H., Fereshetian A. G., Knopp R. H. et al. A Multicenter, Placebo–Controlled, Dose– Ranging Study of Atorvastatin. J Cardiovasc Pharmacol Ther 1998, 3 (2): 119-124.

16. Michael J., Haller1., Jennifer M. et al. Pediatric Atorvastatin in Diabetes Trial (PADIT): A Pilot Study to Determine the Effect of Atorvastatin on Arterial Stiffness and Endothelial Function in Children with Type 1 Diabetes Mellitus. Journal of Pediatric Endocrinology & Metabolism 2009, 22: 65-68.

17. Pfizer Inc. Data on file. New York, NY; 2002.

18. Law M. R., Wald N. J., Thompson S. G. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ 1994, 308: 367-372. 7.

19. Pedro-Botet J., Schaefer E. J., Bakker-Arkema R.G. et al. Apolipoprotein E genotype affects plasma lipid response to atorvastatin in a gender specific manner. Atherosclerosis 2001, 158 (1): 183-93.

20. Barter P. J., Brandrup-Wognsen G., Palmer M. K. et al. Effect of statins on HDL–C: a complex process unrelated to changes in LDL–C: analysis of the VOYAGER Database. J Lipid Res 2010, 51 (6): 1546-53.

21. Stein E. A. Adult treatment panel III and the management of dyslipidemia risk factors. Postgrad Med 2002, 112 (4 Suppl): 12–7.

22. Nicholls S.J, Tuzcu E. M., Sipahi I. et al. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA 2007, 297 (5): 499-508.

23. Insull W., Kafonek S., Goldner D., Zieve F. Comparison of efficacy and safety of atorvastatin (10mg) with simvastatin (10mg) at six weeks. ASSET Investigators. Am J Cardiol 2001, 87: 554-559

24. Martineau P., Gaw A., de Teresa E. et al. Effect of individualizing starting doses of a statin according to baseline LDL-cholesterol levels on achieving cholesterol targets: the achieve cholesterol targets fast with atorvastatin stratified titration (ACTFAST) study. Atherosclerosis. 2007 Mar, 191 (1): 135-46.

25. Briel M., Ferreira-Gonzalez I., You J. J. et al. Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and metaregression analysis. BMJ 2009, 338: b92.

26. Forrest M. J., Bloomfield D., Briscoe R. J. Torcetrapibinduced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone. British Journal of Pharmacology 2008, 154: 1465-1473.

27. Mullins C. D., Rattinger G. B., Kuznik A., Koren M. J. Cost-Effectiveness of Intensive Atorvastatin Treatment in High-Risk Patients Compared with Usual Care in a Postgeneric Statin Market: Economic Analysis of the Aggressive Lipid-Lowering Initiation Abates New Cardiac Events (ALLIANCE) Study. Clin Ther., 2008, 30: 2204-2216.

28. Kanamitsu M., Ebisuzaki W., Woollen J. et al. NCEP-DEO AMIP-II Reanalysis (R-2). Bull of the Atmos Met Soc 2002, 83: 1631-1643.

29. Di Pasquale G. Presentation: European practice guidelines for the prevention of cardiovascular diseases in clinical practice. G Ital Cardiol (Rome) 2008, 9 (1): 9–10.

30. Newman C, Tsai J, Szarek M et al. Comparative Safety of Atorvasatin 80 mg versus 10 mg derived from analysis of 49 completed trials in 14236 patients. Am J Cardiology 2006, 97: 61-67.

31. Colhoun H. M., Betteridge D. J., Durrington P. N. et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicenter randomised placebo-controlled trial. Lancet 2004, 364: 685-96.

32. Сусеков А. В. Холестерин липопротеинов низкой плотности (ХС-ЛНП) и ремнантный холестерин неЛВП: нужна ли рокировка для оценки сердечно-сосудистого риска? Медицинский совет, 2013, 9; 50-55.

33. The online-only Data Supplement is available with this article at http://circ.ahajournals.org/lookup/suppl/ doi:10.1161/01.circ.0000437738.63853.7a/-/DC1.

34. Сусеков А. В. Обоснование повышения доз статинов в клинической практике. Терапевтический архив, 2001. 76-80.

35. Expert Dyslipidemia Panel (Scott M. Grundy). An International Atherosclerosis Society Position Paper: Global recommendations for the management of dyslipidemia. Journal of Clinical Lipidology, 2013, 7, 561-565.

36. Gerald F. Watts et al. Integrated guidance on the care of familial hypercholesterolemia from the International FH Foundation. Journal of Clinical Lipidology, 2014, 8, 148-172.